AS

Astrivax

2 known investors

astrivax.com ↗

Astrivax develops virus-targeted immunotherapies using its Launch-iT platform to eliminate cancer-causing viruses before they lead to disease, with an initial focus on HPV-driven cancers. The company targets an oncology therapeutic space for people at risk of virus-driven cancers.

Investors · 2

FU

Fund+Leuven · $5.5M – $16.5M

V-

V-Bio VenturesGhent · $270K – $2.2M